We are no longer accepting applications for the 2024-26 Fellowship cohort. Please check back in September 2024.

Pharmaceutical Industry Fellowships Program


About Our Program

Northeastern University Pharmaceutical Industry Fellowships Program is a two-year program designed to advance the education and training of Pharm.D. graduates in various areas of industry.

Our programs offer fellows an opportunity to work with our innovative biopharmaceutical industry partners while collaborating with Northeastern University faculty in the areas of research, scholarship, and teaching.

We aim to provide fellows with a dynamic environment to develop industry and academic skills to be leaders in their fields.


Fellowship Opportunities

Our program provides opportunities for PharmDs to gain in-depth, hands on specialized training in a range of specialty areas, including:

  • Clinical Development 
  • Clinical and Quantitative Pharmacology   
  • Clinical Scientist 
  • Commercial Oncology 
  • Global Medical Information 
  • Global Medical Publications
  • Global Patient Safety and Risk Management 
  • Global Scientific Communications 
  • HEOR 
  • Medical Affairs  
  • North American Commercial  
  • Real World Evidence and Epidemiology
  • Regulatory Affairs    

*Takeda Global Medical Affairs and Clinical Scientist Fellowships have expanded eligibility
to include Ph.D. graduates.

Fellowship Focus Areas


Pursue graduate degrees or certificates in Regulatory Affairs, Business, Public Health, and more through tuition reimbursement.


Perform research with faculty and students. Present data at conferences. Publish your findings. Generate literature.


Teach pharmacy students in various small and large group classes. Earn a teaching certificate of achievement.


Boston has a lot of offer, both social and professionally. Our program takes advantage of it all!

Candidates are selected on a nationally competitive basis.

Eligible candidates must have a Doctor of Pharmacy degree from an ACPE-accredited College of Pharmacy by June 30, 2024.

Candidates are encouraged to apply by the priority application deadline. Applications are accepted on a rolling basis!

Recognizing that the choice of a Post-Doctoral Industry Fellowship is an important decision, Northeastern University, in conjunction with the Alliance of Industry Fellowship Associates (AIFA), has agreed to extend offers for Fellowships no earlier than December 13th 2023.

Refer to the application timeline for more information about our recruitment process.

About Our Partnerships

Learn more about our industry partners and apply to our program!

Fellowship positions available

Abbott logo

As a global leader in diabetes care, Abbott is constantly working to deliver the highest quality products and unwavering support to our customers. Consistent and accurate glucose monitoring is the foundation of any diabetes management plan so we’re committed to continuous improvement in the way patients and professionals measure, track and analyze glucose levels. Our science-driven products empower people living with diabetes. Through our innovative product development program, Abbott has developed many cutting-edge glucose monitoring technologies.

In partnership with Northeastern University, Abbott Diabetes Care is offering a two-year Global Medical Affairs PharmD fellowship.

Alnylam Pharmaceutical logo

In 2015, Alnylam Pharmaceuticals partnered with Northeastern University to offer a unique fellowship opportunity in the heart of Boston. The program set out to equip postdoctoral PharmDs with the skills necessary to develop the advanced medicines of the future, like RNAi. The goal was and remains the same: to cultivate the future leaders of biotechnology and allow fellows to pioneer new therapies for patients. Alnylam fellows are grounded in their core expertise area but utilize the fellowship’s flexibility to branch out and discover other opportunities throughout the organization with personalized rotations. Part of the backbone of the fellowship program is the Northeastern University teaching opportunities which allow fellows to share their knowledge in an educational setting.

Specialty Areas

In partnership with Northeastern University, Alnylam offers 2-year PharmD fellowships in the following specialty areas:

  • Clinical Development
  • Global Medical Information
  • Global Medical Publications
  • Global Patient Safety and Risk Management
  • US Medical Affairs
Apellis logo

The mission at Apellis is to boldly deliver revolutionary therapies for people living with serious diseases by harnessing complement, the foundational part of the human immune system. Vision: A leader in the biotech industry known for compassion, revolutionary science, and contributions to humankind around the world. Apellis is committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3.

In partnership with Northeastern University, Apellis is offering a two-year Global Medical Affairs PharmD fellowship.

Bausch Health logo

Bausch Health Companies Inc. is a global, diversified pharmaceutical company whose mission is to improve people’s lives with our pharmaceutical products. We develop, manufacture and market a range of products primarily in gastroenterology, neurology, dermatology and international pharmaceuticals. With our leading durable brands, we are delivering on our commitments to patients, health care providers, other stakeholders and society as we build an innovative company dedicated to advancing global health. With a robust number of business units such as Ortho Dermatologics and Salix Pharmaceuticals under our umbrella company of Bausch Health, our Fellows are exposed to various therapeutic landscapes throughout their
two-year program.

In partnership with Northeastern University, Bausch Health Companies Inc. is offering a two-year HEOR fellowship.

Blueprint medicines logo

Blueprint Medicines is a global precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we combine our leading expertise in protein kinases with a uniquely targeted, scalable approach to empower the rapid design and development of transformational medicines.

Bridgebio logo

BridgeBio is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. We bridge the gap between remarkable advancements in genetic science in academic institutions and the delivery of meaningful medicines to patients. Founded in 2015, the company has built a portfolio of 30+ drug development programs ranging from preclinical to late-stage development in multiple therapeutic areas including genetic dermatology, precision oncology, cardiology, endocrinology, neurology, pulmonology, and renal disease, with two approved drugs.

In partnership with Northeastern University, BridgeBio is offering a two-year Regulatory Affairs fellowship.

Applications will be accepted on a rolling basis.

Chiesi logo

Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we’re part of a global community of businesses that meet high standards of social and environmental impact.

The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system. Chiesi Global Rare Diseases has successfully developed orphan disease products in the disease states of alpha-mannosidosis, ADA-SCID, and thalassemia. Additionally, Chiesi Global Rare Diseases recently acquired three orphan disease products – metreleptin (Myalept®); octreotide (Mycapssa®); and lomitapide (Juxtapid®).

In partnership with Northeastern University, Chiesi is offering a two-year Global-US Medical Affairs PharmD fellowship.

CSL Seqirus logo

Seqirus is part of CSL Limited (ASX: CSL). As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.

Influenza kills. But at Seqirus, we believe it shouldn’t be that way. As the only vaccine company with a singular global focus on influenza, we work tirelessly on cutting-edge research, transformative technologies and the latest methods of production and distribution. Together with our partners we’re on the front line every day, protecting communities from seasonal influenza and global pandemic threats.Our vision is a world protected from influenza.

In partnership with Northeastern University, CSL Seqirus is offering a two-year Medical Affairs PharmD fellowship.

Flatiron logo

Flatiron Health, Inc.Ⓡ is a healthtech company founded in 2012 and is a world leader in transforming patients’ real-life experiences into knowledge to help accelerate improvements in care and treatments for patients with cancer. We translate patient experiences into real-world evidence (RWE) to improve treatment, inform policy, and advance research. Our unparalleled network supports physicians and other healthcare professionals on the cancer frontlines, and can connect clinical practices and patients directly to research that can expand and improve treatment and care options in oncology.

We are a mission- and values-driven company dedicated to building a workforce that reflects the diversity of those impacted by cancer. Our organization consists of more than 2,500 software engineers, data scientists, biostatisticians, epidemiologists, health professionals and other experts who joined Flatiron to learn from the experiences of people with cancer – and to translate that knowledge into better outcomes for patients.

GSK logo

GSK is a global biopharma company with the ambition and purpose to unite science, technology, and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.

We prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.

IPSEN logo

Ipsen is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Our presence in North America dates back to 1976, and now includes Ipsen’s third global hub right in the heart of the leading global biotech ecosystem in Cambridge, Mass., where a fully integrated biopharmaceutical team across External Innovation and Partnering, R&D, Manufacturing and Commercial operations collaborates.

With Ipsen’s expansion of its footprint in Cambridge, and new North America headquarters in Kendall Square, the group is building a sustainable innovation engine within the biotech community.

In partnership with Northeastern University, Ipsen offers 2-year PharmD fellowships in the following speciality areas:

  • Real World Evidence and Epidemiology
  • Commercial Oncology
  • Medical and Regulatory Affairs
  • Rare Disease Operations and Marketing
Ironwood logo

Ironwood Pharmaceuticals is a patient-focused, biopharmaceutical company on a mission to push the boundaries of the gastrointestinal (GI) field by advancing the treatment of GI diseases and redefining the standard of care for millions of patients.

At Ironwood Pharmaceuticals, we are committed to advancing the treatment of GI diseases and redefining the standard of care for GI patients. As a pioneer and champion in the development of a market-leading therapy for IBS-C and CIC, we are singularly focused on advancing the treatment of GI diseases and continue to challenge what has been done before to shape what the future holds. So, we named ourselves after the Ironwood tree, which can live for thousands of years in the harshest desert, creating a shaded microclimate in which life thrives. Iron, like science, is undeniable and strong. Wood, like artistry and humanity, is flexible, resilient and versatile. The two words together represent our passion for making a positive impact on the health – and lives- of GI patients, their families and communities.

In partnership with Northeastern University, Ironwood Pharmaceuticals offers 2-year PharmD fellowships in the following speciality areas:

  • Clinical Development / Medical Science Affairs
  • Global Patient Safety / Regulatory Affairs
Pacira Biosciences

Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes. Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to providing solutions that address unmet medical needs and improve clinical results.

We are a team of dedicated and highly talented professionals focused on driving improved patient outcomes with opioid-reducing strategies. We are an organization built on high ethical standards, an unwavering commitment to patients, and transparent communications. We have a drive and a desire to improve the world around us and make a meaningful difference in the lives of patients, families, communities, and society.

Praxis logo

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders, or CNS, characterized by neuronal excitation-inhibition imbalance. Praxis is applying insights from genetic epilepsies to both rare and more prevalent neurological disorders, using our understanding of shared biological targets and circuits in the brain.

Trust, Ownership, Curiosity, and Results are foundational in every aspect of our business and are exemplified by each one of our team members. We Dare for More in every aspect of our journey, from the patients we are working for, to the portfolio we build and advance every day, and to ourselves and our relationships.

Sarepta Therapeutics

Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short.

We’re ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world’s largest gene therapy manufacturing capacity. We’re collaborating with health networks and payers, rethinking pricing models for revolutionary new treatments in development. We are in a daily race to transform genetic understanding into genetic medicine. Because every day is an opportunity to save lives stolen by rare disease.

In partnership with Northeastern University, Sarepta Therapeutics is offering a two-year Global Scientific Communications PharmD fellowship.

Takeda logo

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

In partnership with Northeastern University, Takeda offers 2-year PharmD fellowships in the following speciality areas:

  • Clinical Science
  • Global Regulatory Affairs
  • Global Medical Affairs — This position has expanded eligibility to include PhD graduates.

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex’s global headquarters is now located in Boston’s Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry’s top places to work, including 11 consecutive years on Science magazine’s Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign.

In partnership with Northeastern University, Vertex offers 2-year PharmD fellowships in the following speciality areas:

  • Clinical Scientist
  • Clinical and Quantitative Pharmacology
  • Global Medical Affairs
  • Global Regulatory Affairs
  • North America Commercial

Contact Us Today

Please let us know what's on your mind. Have a question for us? Ask away.

Fellowship Faculty and Staff

J. Andrew Orr-Skirvin

PharmD, RPh, BCOP

Chair, Department of Pharmacy and Health Systems Sciences; Director of Pharmaceutical Industry Fellowship Program; Clinical Professor Pharmacy and Health Systems Science

Debra Copeland

PharmD, RPh, FNAP

Clinical Professor; Asst. Dean, Office of Experiential and Continuing Professional Education Pharmacy and Health Systems Science

Michael Gonyeau


Clinical Professor and Assistant Dean of Academic Affairs and Assessment, School Leadership Team, School of Pharmacy and Pharmaceutical Sciences Pharmacy and Health Systems Science

Sherisse Mayala-Nelson

Manager of Fellowships, Industry Fellowship Program Pharmacy and Health Systems Science

Sophia Sawtelle

Program Coordinator, Pharmaceutical Industry Fellowship Program Pharmacy and Health Systems Science

Julia Van

Director of Corporate and Foundation Relations School of Pharmacy and Pharmaceutical Sciences

Jenny Van Amburgh


Assistant Dean of Academic Affairs, Director of Post-Graduate Education, Clinical Professor Pharmacy and Health Systems Science

Karen Stanley


Director of Operations, Finance and Administration School of Pharmacy and Pharmaceutical Sciences